Iovance Biotherapeutics, Inc. (IOVA) |
|
6.11 -0.04 (-0.65%)
|
03-31 16:00 |
|
Open: |
6.14 |
Pre. Close: |
6.15 |
|
High:
|
6.25 |
Low:
|
6.035 |
|
Volume:
|
5,505,028 |
Market Cap:
|
1,370(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:19:43 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 7.9 One year: 8.9 |
| Support: |
Support1: 5.38 Support2: 4.48 |
| Resistance: |
Resistance1: 6.76 Resistance2: 7.61 |
| Pivot: |
6.27 |
| Moving Average: |
MA(5): 6.25  MA(20): 6.39
MA(100): 6.87 MA(250): 9.72 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 57.3 %D(3): 55.8 |
| RSI: |
RSI(14): 43.6 |
| 52-week: |
High: 18.72 Low: 5.38 |
| Average Vol(K): |
3-Month: 4,091 (K) 10-Days: 4,119 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IOVA ] has closed above bottom band by 38.0%. Bollinger Bands are 28.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.76 - 6.8 |
6.8 - 6.82 |
|
Low:
|
6.05 - 6.08 |
6.08 - 6.1 |
|
Close:
|
6.1 - 6.15 |
6.15 - 6.2 |
|
Company Description |
|
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. |
Headline News |
Fri, 31 Mar 2023
Keeping Track: More Rx-To-OTC Switches On Deck After US FDA's ... - Pink Sheet
Mon, 27 Mar 2023
Possible title Iovance Biotherapeutics Share Price Surges Reason ... - Best Stocks
Fri, 24 Mar 2023
Stocks to Watch: Motorsport Games, Berkshire Grey, Iovance Biotherapeutics - MarketWatch
Fri, 24 Mar 2023
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average ... - MarketBeat
Fri, 24 Mar 2023
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma - Yahoo Finance
Thu, 23 Mar 2023
Hennion & Walsh Asset Management Inc. Has $1.08 Million Stock ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
224 (M) |
| Shares Float |
193 (M) |
|
% Held by Insiders
|
0.3 (%) |
|
% Held by Institutions
|
89.8 (%) |
|
Shares Short
|
19,330 (K) |
|
Shares Short P.Month
|
20,690 (K) |
Stock Financials |
|
EPS
|
-2.43 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.66 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-34.6 |
|
Return on Equity (ttm)
|
-70.7 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.74 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-293 (M) |
|
Levered Free Cash Flow
|
-174 (M) |
Stock Valuations |
|
PE Ratio
|
-2.53 |
|
PEG Ratio
|
0.1 |
|
Price to Book value
|
2.29 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-4.68 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
